Completed PHASE2 INTERVENTIONAL 4-arm NCT04426968

A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B

A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect Relationship Study of Hepalatide for Injection Combined With Pegylated Interferon in Subjects With Chronic Hepatitis B

Sponsor: Shanghai HEP Pharmaceutical Co., Ltd.

Conditions Hepatitis B, Chronic

Interventions Hepalatide 2.1mg Hepalatide 4.2mg Hepalatide 6.3mg Pegylated Interferon placebo 2.1mg placebo 4.2mg placebo 6.3mg

Updated 11 times since 2020 Last updated: Jan 22, 2025 Started: Jun 18, 2021 Primary completion: Nov 1, 2023 Completion: Nov 29, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hepatitis B, Chronic and is currently completed. Shanghai HEP Pharmaceutical Co., Ltd. leads this study, which shows 11 recorded versions since 2021 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

11 versions recorded

Feb 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Feb 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2024 — Jul 2024 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jan 2023 — Jan 2024 [monthly]

Recruiting PHASE2

▶ Show 6 earlier versions

Mar 2022 — Jan 2023 [monthly]

Recruiting PHASE2
Dec 2021 — Mar 2022 [monthly]

Recruiting PHASE2
Sep 2021 — Dec 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE2
Jan 2021 — Apr 2021 [monthly]

Not Yet Recruiting PHASE2
Jul 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai HEP Pharmaceutical Co., Ltd.

Data source: Shanghai HEP Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Chizhou, China , Chongqing, China , Nanchang, China , Nanjing, China , Qingyuan, China , Shanghai, China , Shenyang, China , Zhengzhou, China and 1 more location